FDA-cleared profile

aBSI

EXINI Diagnostics AB · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.

Clinical role
Cloud-based lesion marking, quantitative Bone Scan Index calculation, longitudinal display, and reporting.
Images and patients
PET/SPECT/Nuclear Medicine · Bone
Key limitation
Keep in mind: Although unlikely, an incorrect BSI value could potentially contribute to the risk of an incorrect therapy decision or delay in the delivery of appropriate care.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Bone Input: DICOM 3 whole-body bone scans and SPECT; CT images are not accepted, and static (partial) bone scans are not required or used for BSI calculation.
  • Who uses it?Intended users: Trained healthcare professionals and researchers interpreting nuclear-medicine bone scans.
  • What does the software produce?Output: Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.
  • What is its most important limitation?Key limitation: Although unlikely, an incorrect BSI value could potentially contribute to the risk of an incorrect therapy decision or delay in the delivery of appropriate care.

Clinical takeaway. Clinical role: aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.

Evidence takeaway. Evidence from the reviewed source record: K191262 reports analytical, reproducibility, phantom, and two clinical studies. In a 721-patient phase III analysis, baseline aBSI was associated with overall survival and remained independently associated after adjustment; a separate 169-patient analysis found that an aBSI increase of 0.6 had the same 0.52 association with time to radiographic bone progression as PCWG criteria.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Cloud-based lesion marking, quantitative Bone Scan Index calculation, longitudinal display, and reporting.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM 3 whole-body bone scans and SPECT; CT images are not accepted, and static (partial) bone scans are not required or used for BSI calculation.
  • Exact FDA submission
  • Checked 2026-09-19

The exact subject-device comparison provides the DICOM 3 input types and the CT/static-partial boundary.

Output and clinician action
Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Healthcare clinics and research workflows using whole-body bone scintigraphy or SPECT.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained healthcare professionals and researchers interpreting nuclear-medicine bone scans.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Although unlikely, an incorrect BSI value could potentially contribute to the risk of an incorrect therapy decision or delay in the delivery of appropriate care.
  • Exact FDA submission
  • Checked 2026-09-19

The exact software-risk discussion states this consequence boundary; the packet does not state the prior threshold, acquisition, urinary-activity, or standalone-diagnosis wording.

Evidence summary
K191262 reports analytical, reproducibility, phantom, and two clinical studies. In a 721-patient phase III analysis, baseline aBSI was associated with overall survival and remained independently associated after adjustment; a separate 169-patient analysis found that an aBSI increase of 0.6 had the same 0.52 association with time to radiographic bone progression as PCWG criteria.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K191262 reports analytical, reproducibility, phantom, and two clinical studies. In a 721-patient phase III analysis, baseline aBSI was associated with overall survival and remained independently associated after adjustment; a separate 169-patient analysis found that an aBSI increase of 0.6 had the same 0.52 association with time to radiographic bone progression as PCWG criteria.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Phase III evaluable patients

721 patients

  • EndpointAssociation of baseline aBSI with outcomes
  • PopulationaBSI
  • Tested versionaBSI version 3.4 cleared in K191262

Baseline aBSI overall-survival hazard ratio

1.2 hazard ratio

  • EndpointOverall survival per aBSI relationship
  • PopulationaBSI
  • Tested versionaBSI version 3.4 cleared in K191262

Adjusted overall-survival hazard ratio

1.06 hazard ratio

  • EndpointMultivariable overall survival
  • PopulationaBSI
  • Tested versionaBSI version 3.4 cleared in K191262

Progression association

0.52 Kendall tau

  • EndpointaBSI increase of 0.6 and radiographic progression
  • PopulationaBSI
  • Tested versionaBSI version 3.4 cleared in K191262

Earlier-version linearity correlation

0.995 Pearson r

  • EndpointSimulated BSI from 0.10 to 13.0
  • PopulationaBSI
  • Tested versionEXINI bone BSI version 2

Earlier-version interobserver agreement

0.96 kappa

  • EndpointAutomated change interpretation
  • PopulationaBSI
  • Tested versionEXINI bone BSI version 2

Staging sensitivity at BSI greater than 0

100 %

  • EndpointMetastasis classification against available reference
  • PopulationaBSI
  • Tested versionEXINI Bone version 1.6.2

Staging specificity at BSI greater than 0

36.2 %

  • EndpointMetastasis classification against available reference
  • PopulationaBSI
  • Tested versionEXINI Bone version 1.6.2

K191262 FDA performance package for aBSI

  • DesignManufacturer analytical validation plus prospective planned phase III and retrospective clinical-outcome analyses
  • PopulationMen with metastatic castration-resistant prostate cancer
  • Scopeexact submission
  • Tested versionaBSI version 3.4 cleared in K191262
  • Samplen=721
  • Sites241
  • IndependenceSponsor or vendor study

K191262

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Analytic validation of automated Bone Scan Index

  • DesignIndependent analytic simulation, repeat-scan, and follow-up agreement studies
  • PopulationSimulated bone scans and patients with metastatic prostate cancer
  • Scopeproduct family
  • Tested versionEXINI bone BSI version 2; not exact aBSI 3.4
  • Samplen=173
  • IndependenceIndependent study

PMC4975929

Algorithm-family evidence with an earlier version; includes a documented bladder-region blind spot.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K191262 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 3 whole-body bone scans and SPECT; CT images are not accepted, and static (partial) bone scans are not required or used for BSI calculation.

    Scope: Exact FDA submission. The exact subject-device comparison provides the DICOM 3 input types and the CT/static-partial boundary.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K191262: aBSI

  2. Routing

    Source context, not route validation: Cloud service accessed through a personal login on Windows or macOS Chrome, with image upload from a local or network folder; validate DICOM transfer, identity, patient matching, longitudinal alignment, browser support, and result export.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K191262: aBSI

  3. AI processing

    Source context, not route validation: Cloud-hosted software service accessed by a supported browser; exact tenancy, region, retention, identity, audit, and support controls require vendor confirmation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K191262: aBSI

  4. Returned objects

    Source context, not route validation: Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K191262: aBSI

  5. Viewer/worklist/report

    Unresolved route: Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K191262: aBSI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-hosted software service accessed by a supported browser; exact tenancy, region, retention, identity, audit, and support controls require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Cloud service accessed through a personal login on Windows or macOS Chrome, with image upload from a local or network folder; validate DICOM transfer, identity, patient matching, longitudinal alignment, browser support, and result export.
  • Exact FDA submission
  • Checked 2026-09-03
Security
K191262 describes cloud hosting and personal login but not a complete security architecture. Obtain current encryption, identity, audit, data residency, retention, vulnerability, backup, support-access, and incident-response evidence.
  • Exact FDA submission
  • Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training
Only trained healthcare professionals and researchers interpreting nuclear-medicine bone scans. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: aBSI is quantitative decision support, not a standalone metastasis diagnosis. Threshold-dependent staging performance can trade sensitivity against specificity, and scan counts, acquisition speed, urinary activity, protocol, and disease burden can affect results.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K191262 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Cloud service accessed through a personal login on Windows or macOS Chrome, with image upload from a local or network folder; validate DICOM transfer, identity, patient matching, longitudinal alignment, browser support, and result export.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. aBSI is quantitative decision support, not a standalone metastasis diagnosis. Threshold-dependent staging performance can trade sensitivity against specificity, and scan counts, acquisition speed, urinary activity, protocol, and disease burden can affect results.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: aBSI is quantitative decision support, not a standalone metastasis diagnosis. Threshold-dependent staging performance can trade sensitivity against specificity, and scan counts, acquisition speed, urinary activity, protocol, and disease burden can affect results.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K191262
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication names nuclear-medicine imaging and the subject-device comparison lists DICOM 3 whole-body bone scans and SPECT; it does not support the dossier's PET wording. Controlled directory display reconciled from exact FDA wording: Nuclear medicine (NM) imaging, including DICOM 3 whole-body bone scans and SPECT. -> PET/SPECT/Nuclear Medicine.

Anatomy
Bone
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-08-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K191262: aBSI

    U.S. Food and Drug Administration - Published 2019-08-05 - Accessed 2026-09-19

    Scope: purpose, anatomy, intendedUsers, output, evidenceSummary, modality, input, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Analytic validation of automated Bone Scan Index as an imaging biomarker

    Journal of Nuclear Medicine - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring

  8. Prospective evaluation of computer-assisted skeletal-lesion analysis for prostate-cancer staging

    BMC Medical Imaging - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring

Research history

  1. K191262 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241350

Clarify DL

GE Medical Systems Israel, Functional Imaging

Authorized purpose: Clarify DL is a deep-learning reconstruction function intended to reduce noise and improve image quality of nuclear-medicine bone SPECT scintigraphy for all ages on the supported Xeleris V and StarGuide platforms.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Bone
Decision
2025-01-03
FDA-cleared K221680

Xeleris V Processing and Review System

GE Healthcare

Authorized purpose: The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications for DaTQUANT, lung analysis, brain analysis, coronary-flow reserve, prostate-cancer bone metastases, liver shunt and dose calculations, and monitoring of patient radiation doses from nuclear-medicine imaging data.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, lung, brain, liver, cardiac, coronary, and other anatomy represented in labeled nuclear-medicine studies
Decision
2023-03-01
FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K251153

Aurora

GE Medical Systems Israel

Authorized purpose: Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance, and monitoring. K251153 adds deep-learning kidney segmentation to dynamic renal scintigraphy.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-06-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history